Q4 2025 Cipher Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Cipher Pharmaceuticals Inc (CPHRF) reported a more than doubling of revenue and earnings in 2025 compared to the previous full fiscal year, driven by the acquisition of the US-based Natroba business.
- Sales from Natroba and its authorized generic, Spinosad, increased by 14% in Q4 2025 compared to the same quarter in the previous year.
- The Natroba business achieved a strong gross margin of 83% in 2025, contributing significantly to the company's adjusted EBITDA.
- Cipher Pharmaceuticals Inc (CPHRF) successfully reduced its revolving credit facility balance from $40 million to $5 million within 18 months, demonstrating strong cash generation and disciplined capital allocation.
- The company launched a direct-to-consumer (DTC) sales model for Natroba, aiming to enhance accessibility and convenience for consumers, which could potentially lower sales costs and increase volumes.
- Cipher Pharmaceuticals Inc (CPHRF) experienced a decrease in licensing revenue, primarily due to reduced revenue from product shipments and lower net sales realized by distribution partners.
- The Absorica portfolio in the US faced pressure from a highly competitive market saturated by generic competition, leading to a decline in licensing revenue.
- Selling, general, and administrative expenses increased by 11% in 2025 compared to 2024, partly due to a full year of expenses for the acquired US business.
- The company is facing challenges in securing international out-licensing deals for Natroba, primarily due to pricing issues in non-US markets.
- The pipeline for new product opportunities, such as MOB-015, remains uncertain, with no high priority given to its development at this time.
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Cipher Pharmaceuticals quarterly conference call for the company's fourth quarter and full year 2025 results. (Operator Instructions) As a reminder, this conference is being recorded today, Friday, March 13, 2026. On behalf of the speakers that follow, listeners are cautioned that today's presentation and the responses to questions may contain forward-looking statements within the meaning of the safe harbor provisions of the Canadian provincial securities laws.
Forward-looking statements involve risks and uncertainties and undue reliance should not be placed on such statements. Certain material factors or assumptions are implied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements.
For additional information about factors that cause results to vary, please refer to the risks identified in the company's annual information form and other filings with Canadian regulatory authorities, except as required by Canadian securities laws. The
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
